TCGA-OR-A5LA-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.535
- ALLOGRAFT_REJECTION+0.431
- FATTY_ACID_METABOLISM+0.406
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.396
- ADIPOGENESIS+0.371
- INTERFERON_GAMMA_RESPONSE+0.346
- COMPLEMENT+0.331
- INTERFERON_ALPHA_RESPONSE+0.323
- IL6_JAK_STAT3_SIGNALING+0.266
- COAGULATION+0.263
Top 10 suppressed
- G2M_CHECKPOINT-0.546
- E2F_TARGETS-0.513
- MITOTIC_SPINDLE-0.450
- TGF_BETA_SIGNALING-0.332
- WNT_BETA_CATENIN_SIGNALING-0.257
- UNFOLDED_PROTEIN_RESPONSE-0.231
- CHOLESTEROL_HOMEOSTASIS-0.191
- HEDGEHOG_SIGNALING-0.180
- UV_RESPONSE_DN-0.173
- MYC_TARGETS_V2-0.165
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_PQ6QEVE8 | Ganglioglioma | — | 0.849 |
| 2 | TCGA-OR-A5L5-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.848 |
| 3 | ERR2598280 | fetal | fetal | 0.838 |
| 4 | BS_XQ5SFW35 | high-grade glioma | — | 0.835 |
| 5 | SRR656167 | GTEX | — | 0.834 |
| 6 | DRR168526 | — | — | 0.826 |
| 7 | MDT-AP-2183 | Med | Medulloblastoma | 0.820 |
| 8 | BS_CS66RYDA | Schwannoma | — | 0.818 |
| 9 | ERR2598328 | fetal | fetal | 0.817 |
| 10 | TCGA-CQ-6222-01A-11R-1915-07 | — | — | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.535 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.431 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.406 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.396 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.371 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.346 | Idelalisib | — uncovered |
| COMPLEMENT | 0.331 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.323 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.266 | Inavolisib | — uncovered |
| COAGULATION | 0.263 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.258 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.252 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.247 | Inavolisib | — uncovered |
| MYOGENESIS | 0.241 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.228 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.227 | Inavolisib | — uncovered |
| APOPTOSIS | 0.214 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.186 | Idelalisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |